Bridgebio Entered into an Exclusive License Agreement with BMS to Develop and Commercialize BBP-398 for the Treatment of Cancer
Shots:
- BridgeBio to receive $90M up front, ~$815M in development, regulatory & sales milestones along with royalties. BMS will be responsible to fund the other development & commercial activities
- BridgeBio obtains an option to acquire higher royalties in the US along with funding for a portion of development costs upon the initiation of registrational studies & continues to lead the P-I trial of BBP-398 as monothx. & in combination with additional support from BMS
- In the 2021 agreement, BridgeBio & BMS collaborated to evaluate BBP-398 + Opdivo for advanced solid tumors with KRAS mutations. BridgeBio expands its P-I trial for solid tumors driven by mutations in the MAPK signaling pathway
Ref: Bridgebio | Image: Bridgebio
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
